The elimination kinetics of cefotetan (YM09330), a new parenteral semisynthetic cephamycin derivative, were studied in eight healthy volunteers and 41 patients with renal insufficiency after the administration of a single 500-mg dose intravenously. Concentrations of cefotetan in serum and urine were determined by both bioassay and high-pressure liquid chromatography. The pharmacokinetic parameters for cefotetan were calculated on the basis of a two-compartment open model. Serum concentrations of cefotetan immediately after administration were approximately 180 ,ug/ml in all subjects regardless offunction; however, serum concentrations during the P-phase increased directly with the degree of renal impairment. The mean serum half-life during the p-phase was 3.0 h in normal subjects as compared with 13.1 h in hemodialysis patients. There was a linear correlation (P < 0.0001) between the elimination rate constant of cefotetan and creatinine clearance. The mean cumulative urinary recovery of cefotetan in the 24-h urine was 83.3% of the administered dose in normal subjects and decreased with reduced renal function.
Cefotetan (YM09330) is a new semisynthetic parenteral cephamycin derivative characterized by high activity against gram-negative bacteria and marked stability to hydrolysis by 1-lactamases (5, 15) . Cefotetan has a longer half-life than other cephalosporins and in various experimental animals is eliminated mainly by the kidneys (6) . The present report is concerned with the pharmacokinetics of cefotetan as observed in normal volunteers and patients with various degrees of renal impairment, to whom a single dose of the agent had been administered intravenously.
(These results were presented in part at the 12th International Congress of Chemotherapy, Florence, Italy, 1981.) MATERIALS AND METHODS
This study was conducted in eight healthy adult volunteers and 41 patients with various degrees of renal impairment. The renal functions of all subjects were stable during the study. Informed consent was obtained from each individual before the study. The mean weight of the subjects was 52.8 kg (range, 36 to 80 kg), and the mean age was 59.4 years (range, 27 to 88 years). None had received an antimicrobial agent for more than 1 week before the study. Endogenous creatinine clearance (icr [24 h]) corrected for 1.73 m2 of body surface area was used as an indicator of renal function and the basis for dividing the subjects into five groups. Group 1 was composed of eight healthy volunteers with Ccrs of 110 to 167 ml/min. Group 2 included eight patients with Ccrs of 68.6 to 93.9 ml/ min. Group 3 was made up of 16 patients with Ccs of 30.9 to 57.7 ml/min. Group 4 was composed of 10 patients with C,,s of 8.1 to 28.2 ml/min. Group 5 included seven patients with Ccrs of 0 to 7.8 ml/min. All patients in the latter group were on periodic hemodialysis; five were examined both during and between the hemodialysis session.
The cefotetan for this study was supplied by Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan. All subjects received a single 500-mg dose of cefotetan dissolved in 20 ml of physiological saline, which was injected intravenously over 3 min. Blood samples were obtained just before injection and at 5, 15, and 30 min; at 1, 2, 5, 8, and 24 h after injection; and at 48 h postdrug in groups 3, 4, and 5. Urine samples were collected at intervals of 0 to 2, 2 to 4, 4 to 6, 6 to 8, and 8 to 24 h after dosage and at 24 to 48 h in groups 3, 4, and 5. To investigate potential differences in pharmacokinetics between episodes of hemodialysis and during hemodialysis, serum concentrations were measured for 5 h in five hemodialysis patients of group 5 by a crossover design. Blood samples were taken at 5, 15, and 30 min and 1, 2, and 5 h after the injection of 500 mg of cefotetan; this dose was administered approximately 1 h after the beginning of hemodialysis, when blood-flow through the dialyzer was stabilized. mean urinary recovery during 24 h amounted to 83.3% in normal subjects and decreased progressively with reduced renal function to reach 4.7% of the dose in hemodialysis patients. In groups 3, 4, and 5, mean urinary recoveries were 4.5, 5.2, and 2.5%, respectively, of the dose during the period from 24 to 48 h. Table 2 also shows urinary excretions of cefotetan and its tautomer as measured by HPLC. The 24-h cumulative urinary recovery of the tautomer in urine ranged from 0.3 to 7.3% of the parent compound in each group and could not be correlated with renal function.
The pharmacokinetic parameters of cefotetan in each group are summarized in Table 3 . The mean serum concentrations in the central compartment at time zero in each group ranged from 154 to 183 ,ug/ml; there was no significant correlation with Ccr. Statistical analysis demonstrated a significant correlation between the Ccr and the elimination rate constant of cefotetan (P < 0.001) and between the Ccr and ,-phase rate constant of cefotetan (P < 0.001). The mean serum half-life during the a-phase (tl/23,a) in each group ranged from 0.129 to 0.202 h; there was no significant correlation with Ccr. The mean serum half-life during the p-phase (ti120), 3 .00 h in normal subjects, was prolonged to 13.11 h in hemodialysis patients. A hyperbolic relationship was observed between the Ccr and the t1/2p. The mean distribution volumes of the central compartment and at steady state were 3.31 and 8.04 liters or 5.5 and 13.3%, respectively, of body weight in normal subjects. These values were not influenced by the severity of renal impairment. Total body and renal clearances were corrected for 1.73 m2 of body surface area. The mean total body clearance and renal clearance of cefotetan were 38.7 and 32.3 ml/min in normal subjects and decreased with reduced renal function. The results demonstrated significant correlations between the Ccr and the total body clearance (P < 0,0001), between the Ccr and the renal clearance (P < 0.0001), and between the total body clearance and the renal clearance (P < 0.0001). The mean area under the serum concentration curve (AUCO) was 254.0 xg * h/ml in normal subjects and increased inversely to the reduced renal function. There was a hyperbolic relationship between the Ccr and the AUC. .E I urinary excretion was a major route of elimination. The reason for the increase of serum concentrations of cefotetan in renal-insufficiency patients is considered to be the slower renal excretion of the drug. In 24-h urine, less than 10% of the administered dose of cefotetan was found in the form of its tautomer, regardless of degrees of renal impairment. Since the antimicrobial activities of the tautomer were the same as those of cefotetan in media of various pH's (6), the values of urinary recoveries determined by bioassay were similar to the total values of cefotetan and the tautomer separately determined by HPLC. The cefotetan-to-tautomer ratios were not influenced by the severity of renal impairment.
The data on cefotetan concentrations in serum best fit the biexponential equation; hence, a twocompartment open model was used to calculate pharmacokinetic parameters. The tl1 of cefotetan in normal subjects (approximately 3 h) is longer than those of most other parenteral cephalosporins (10), including the expanded-spectrum cephems-2.07 h for cefoperazone (1), 2.23 h for moxalactam (14), 1.13 h for cefotaxime (4) , and 1.9 h for ceftizoxime (9)-but is shorter than the t1/2 of 8.8 h recently reported for ceftriaxone (13) . The tl2p of cefotetan was prolonged as renal function decreased, being four times as long in patients with the most severely impaired renad function (group 5) as in normal subjects (group 1). This prolongation of the tl2p for cefotetan was smaller than those for other cephems; for example, it was 6 to 28 times greater for cefazolin (2) , cefamandole (7) , cefmetazole (11) , cefoxitin (3) , and moxalactam (12) . Since the metabolite of cefotetan resulting from enzymatic degradation was not detected in the plasma, urine, or. bile of various animals (6) , the slight prolongation of the tl2p, of cefotetan in renal-insufficiency patients could be due to a comparatively large elimination by another route, perhaps by biliary excretion. In rats, 48% of the dose was recovered in the bile within 24 h, and approximately 100% of the dose was recovered in the urine and bile combined (6) . Total body clearance decreased in parallel with the reduction in the Ccr, whereas nonrenal clearance (total body clearance -renal clearance) was constant (6.4 to 11.3 ml/min) regardless of the degree of renal impairment. Therfore, biliary excretion may be a major pathway of cefotetan in patients with severe renal impairment. The value of the AUC for cefotetan in normal subjects was great compared with the results reported for most othercephems. This was mainly due to the long tl/2p of cefotetan. The t1/2 and the AUC of cefotetan were increased in patients with severe renal dysfunction, whereas slight increases were noted in patients with CcrS of 
